Stockreport

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva SE - American Depositary Shares  (VALN) 
PDF Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA [Read more]